


Varespladib methyl

Chemical Properties

CAS No. :	172733-08-3
Formula:	C ₂₂ H ₂₂ N ₂ O ₅
Molecular Weight:	394.42
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Varespladib methyl (LY333013), a bioavailable prodrug of Varespladib, is a selective group II secretory phospholipase A2 inhibitor.
Targets(IC50)	Phospholipase
In vitro	Varespladib methyl display high-level secretory PLA2 inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents [1].

Solubility Information

Solubility	DMSO: 95 mg/mL (240.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.68 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5354 mL	12.6768 mL	25.3537 mL
5 mM	0.5071 mL	2.5354 mL	5.0707 mL
10 mM	0.2535 mL	1.2677 mL	2.5354 mL
50 mM	0.0507 mL	0.2535 mL	0.5071 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lewin M, et al. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. *Toxins (Basel)*. 2016 Aug 25;8(9). pii: E248.

Bradley JD, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. *J Rheumatol*. 2005 Mar;32(3):417-23.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481